A novel medication, baxdrostat, is demonstrating promising efficacy in managing dangerously elevated blood pressure levels, particularly in individuals who have not responded to conventional therapies. Results from a significant global clinical trial indicate that patients experienced an average blood pressure reduction of nearly 10 mmHg. This substantial decrease is clinically meaningful, as it can considerably mitigate the risks associated with critical cardiovascular events such as heart attacks, strokes, and the progression of kidney disease. By specifically targeting a hormone responsible for promoting the body’s retention of salt and water, baxdrostat presents a potentially life-changing therapeutic option for millions worldwide grappling with persistently uncontrolled hypertension.
Scientists reveal new blood pressure treatment that works when others fail
By Rupert Blackwood
Investigative journalist based in Sheffield, focusing on technology's impact on society. Rupert specializes in cybercrime's effect on communities, from online fraud targeting elderly residents to cryptocurrency scams. His reporting examines social media manipulation, digital surveillance, and how criminal networks operate in cyberspace. With expertise in computer systems, he connects technical complexity with real-world consequences for ordinary people